|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
|
CA2682147C
(en)
|
2007-03-30 |
2017-08-08 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
|
BRPI0812384A2
(pt)
*
|
2007-05-22 |
2014-12-02 |
Novartis Ag |
Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21
|
|
EP2296690B1
(en)
|
2008-06-04 |
2016-11-30 |
Amgen, Inc |
Fgf21 mutants and uses thereof
|
|
AU2013211503C1
(en)
*
|
2008-10-10 |
2016-09-29 |
Amgen Inc. |
FGF21 mutants and uses thereof
|
|
JP5878757B2
(ja)
|
2008-10-10 |
2016-03-08 |
アムジエン・インコーポレーテツド |
Ｆｇｆ２１変異体およびその使用
|
|
BRPI1007313A2
(pt)
|
2009-01-23 |
2016-02-10 |
Novo Nordisk As |
derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.
|
|
EP2427207B1
(en)
*
|
2009-05-05 |
2017-08-16 |
Amgen, Inc |
Fgf21 mutants and uses thereof
|
|
HRP20240135T1
(hr)
|
2009-05-05 |
2024-04-12 |
Amgen Inc. |
Fgf21 mutanti i njihove upotrebe
|
|
WO2011154349A2
(en)
|
2010-06-08 |
2011-12-15 |
Novo Nordisk A/S |
Fgf21 analogues and derivatives
|
|
US8324160B2
(en)
|
2009-06-17 |
2012-12-04 |
Amgen Inc. |
Chimeric polypeptides and uses thereof
|
|
WO2011006072A2
(en)
*
|
2009-07-10 |
2011-01-13 |
Northwestern University |
Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
|
|
EP2679234A3
(en)
|
2009-12-02 |
2014-04-23 |
Amgen Inc. |
Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
|
|
UA109888C2
(uk)
*
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
EP2460527A1
(en)
|
2010-01-21 |
2012-06-06 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
CA2796055A1
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
Human fgf receptor and .beta.-klotho binding proteins
|
|
CA2796459C
(en)
|
2010-04-16 |
2016-05-24 |
Salk Institute For Biological Studies |
Methods for treating metabolic disorders using fgf-1
|
|
EP2595647A1
(en)
|
2010-07-20 |
2013-05-29 |
Novo Nordisk A/S |
N-terminal modified fgf21 compounds
|
|
JP2014500248A
(ja)
|
2010-11-05 |
2014-01-09 |
コヴェックス・テクノロジーズ・アイルランド・リミテッド |
抗糖尿病化合物
|
|
US8754044B2
(en)
|
2011-05-03 |
2014-06-17 |
Northwestern University |
Neuroprotection by hepatic cells and hepatocyte secretory factors
|
|
SI2710035T1
(sl)
|
2011-05-16 |
2017-07-31 |
F. Hoffmann-La Roche Ag |
Agonisti FGFR1 in tehnike njihove uporabe
|
|
WO2013006486A2
(en)
|
2011-07-01 |
2013-01-10 |
Ngm Biopharmaceuticals, Inc. |
Compositions, uses and methods for treatment of metabolic disorders and diseases
|
|
EP2548570A1
(en)
|
2011-07-19 |
2013-01-23 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
JP6165168B2
(ja)
|
2011-12-22 |
2017-07-19 |
ファイザー・インク |
抗糖尿病化合物
|
|
SMT201700488T1
(it)
|
2012-02-15 |
2017-11-15 |
Novo Nordisk As |
Anticorpi che legano e bloccano il recettore d'innesco espresso sulle cellule mieloidi-1 (trem-1)
|
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
|
JP6400480B2
(ja)
|
2012-02-15 |
2018-10-03 |
ノヴォ ノルディスク アー／エス |
ペプチドグリカン認識タンパク質１に結合する抗体
|
|
US9475856B2
(en)
|
2012-03-02 |
2016-10-25 |
New York University |
Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
|
|
US9474785B2
(en)
|
2012-06-07 |
2016-10-25 |
New York University |
Chimeric fibroblast growth factor 19 proteins and methods of use
|
|
US9464126B2
(en)
|
2012-06-07 |
2016-10-11 |
New York University |
Chimeric fibroblast growth factor 21 proteins and methods of use
|
|
US9657075B2
(en)
|
2012-06-07 |
2017-05-23 |
New York University |
Chimeric fibroblast growth factor 23 proteins and methods of use
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
HK1214832A1
(zh)
|
2012-11-28 |
2016-08-05 |
恩格姆生物制药公司 |
用於代謝病症和疾病治療的組合物和方法
|
|
MX383664B
(es)
|
2012-12-27 |
2025-03-14 |
Ngm Biopharmaceuticals Inc |
Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
US9550820B2
(en)
|
2013-02-22 |
2017-01-24 |
New York University |
Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
|
|
WO2015061331A1
(en)
|
2013-10-21 |
2015-04-30 |
Salk Institute For Biological Studies |
Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
|
|
AU2014340241B2
(en)
|
2013-10-21 |
2018-11-01 |
Salk Institute For Biological Studies |
Mutated fibroblast growth factor (FGF) 1 and methods of use
|
|
WO2015065897A1
(en)
|
2013-10-28 |
2015-05-07 |
Ngm Biopharmaceuticals, Inc. |
Cancer models and associated methods
|
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
|
PT3097122T
(pt)
|
2014-01-24 |
2020-07-21 |
Ngm Biopharmaceuticals Inc |
Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
|
|
US10398758B2
(en)
|
2014-05-28 |
2019-09-03 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
|
|
WO2015195509A2
(en)
|
2014-06-16 |
2015-12-23 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
EP3172232B1
(en)
|
2014-07-17 |
2023-12-27 |
Novo Nordisk A/S |
Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
|
|
CN114129709A
(zh)
|
2014-10-23 |
2022-03-04 |
恩格姆生物制药公司 |
包含肽变异体的药物组合物及其使用方法
|
|
SMT202100388T1
(it)
|
2014-10-24 |
2021-09-14 |
Bristol Myers Squibb Co |
Polipeptidi fgf-21 modificati e loro usi
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
AR103246A1
(es)
|
2014-12-23 |
2017-04-26 |
Novo Nordiks As |
Derivados de fgf21 y sus usos
|
|
WO2017019957A2
(en)
|
2015-07-29 |
2017-02-02 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
|
WO2017075260A1
(en)
|
2015-10-30 |
2017-05-04 |
Salk Institute For Biological Studies |
Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs
|
|
JP6728352B2
(ja)
|
2015-11-09 |
2020-07-22 |
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド |
胆汁酸に関係した障害の治療方法
|
|
TW201731867A
(zh)
|
2015-12-02 |
2017-09-16 |
賽諾菲公司 |
Ｆｇｆ２１變異體
|
|
CN107759697B
(zh)
|
2016-08-19 |
2023-03-24 |
安源医药科技（上海）有限公司 |
制备融合蛋白的方法
|
|
US11123438B2
(en)
|
2016-08-19 |
2021-09-21 |
Ampsource Biopharma Shanghai Inc. |
Linker peptide for constructing fusion protein
|
|
CN106279437B
(zh)
|
2016-08-19 |
2017-10-31 |
安源医药科技（上海）有限公司 |
高糖基化人凝血因子viii融合蛋白及其制备方法与用途
|
|
EP3503882A4
(en)
|
2016-08-26 |
2020-07-29 |
NGM Biopharmaceuticals, Inc. |
METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
|
|
EP4470551A3
(en)
|
2017-03-14 |
2025-02-26 |
Sunshine Lake Pharma Co., Ltd. |
Dual-target fusion proteins comprising the fc portion of an immunoglobulin
|
|
MX2020002206A
(es)
|
2017-09-08 |
2020-07-20 |
Bristol Myers Squibb Co |
Factor de crecimiento de fibroblastos 21 (fgf-21) modificado para usarse en metodos para tratar la esteatohepatitis no alcoholica (nash).
|
|
CN109929806B
(zh)
|
2017-12-19 |
2020-05-08 |
北京吉源生物科技有限公司 |
一种表达glp1和fgf21的干细胞及其用途
|
|
EP3774902A1
(en)
|
2018-04-02 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anti-trem-1 antibodies and uses thereof
|
|
CA3104686A1
(en)
|
2018-07-03 |
2020-01-09 |
Bristol-Myers Squibb Company |
Fgf-21 formulations
|
|
US20220017570A1
(en)
|
2018-11-05 |
2022-01-20 |
Bristol-Meyers Squibb Company |
Method for purifying pegylated protein
|
|
CN111662373B
(zh)
|
2019-03-05 |
2024-05-14 |
广东东阳光药业股份有限公司 |
一种多肽分子及其应用
|
|
US11542309B2
(en)
|
2019-07-31 |
2023-01-03 |
Salk Institute For Biological Studies |
Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
|
|
IL294534A
(en)
|
2020-01-08 |
2022-09-01 |
Bristol Myers Squibb Co |
Fgf-21 conjugate formulations
|
|
US11981718B2
(en)
|
2020-05-27 |
2024-05-14 |
Ampsource Biopharma Shanghai Inc. |
Dual-function protein for lipid and blood glucose regulation
|
|
JP2023538533A
(ja)
|
2020-08-07 |
2023-09-08 |
ブリストル－マイヤーズ スクイブ カンパニー |
線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
|
|
US20240123031A1
(en)
|
2020-11-25 |
2024-04-18 |
Bristol-Myers Squibb Company |
Methods of treating liver diseases
|